Cargando…
Pharmaceutical Pricing Policy in Greece: Toward a Different Path
BACKGROUND: Affordable, accessible, and innovation-promoting pharmaceutical care is essential to the operation of a sustainable health system. External reference pricing (ERP), a common pharmaceutical policy in Europe, suffers today from indigenous weaknesses that may cause market distortions and ba...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005395/ https://www.ncbi.nlm.nih.gov/pubmed/27630983 http://dx.doi.org/10.3389/fpubh.2016.00185 |
_version_ | 1782450918128615424 |
---|---|
author | Souliotis, Kyriakos Papageorgiou, Manto Politi, Anastasia Athanasiadis, Athanasios |
author_facet | Souliotis, Kyriakos Papageorgiou, Manto Politi, Anastasia Athanasiadis, Athanasios |
author_sort | Souliotis, Kyriakos |
collection | PubMed |
description | BACKGROUND: Affordable, accessible, and innovation-promoting pharmaceutical care is essential to the operation of a sustainable health system. External reference pricing (ERP), a common pharmaceutical policy in Europe, suffers today from indigenous weaknesses that may cause market distortions and barriers to care, burdening mostly the weak economies, and hence, raising ethical and political worrying. OBJECTIVES AND METHODS: A non-randomized experiment was conducted, in order to examine the influence of flexible and adaptable to health systems’ affordability ERP structures. Outcomes were assessed by measuring deviations from Greek prices’ level ex ante, as well as effects on pharmaceutical markets affiliated to the European ERP system. RESULTS AND CONCLUSION: Pharmaceutical pricing models that fit prices to income and affordability are better in all aspects, as they produce fairer results, while resulting in low external costs for the European ERP network as a whole. Small sets of reference countries are preferred to large baskets, as they produce similar results, while presenting better qualities by increasing the flexibility of the reimbursement system and the transparency of the market. |
format | Online Article Text |
id | pubmed-5005395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50053952016-09-14 Pharmaceutical Pricing Policy in Greece: Toward a Different Path Souliotis, Kyriakos Papageorgiou, Manto Politi, Anastasia Athanasiadis, Athanasios Front Public Health Public Health BACKGROUND: Affordable, accessible, and innovation-promoting pharmaceutical care is essential to the operation of a sustainable health system. External reference pricing (ERP), a common pharmaceutical policy in Europe, suffers today from indigenous weaknesses that may cause market distortions and barriers to care, burdening mostly the weak economies, and hence, raising ethical and political worrying. OBJECTIVES AND METHODS: A non-randomized experiment was conducted, in order to examine the influence of flexible and adaptable to health systems’ affordability ERP structures. Outcomes were assessed by measuring deviations from Greek prices’ level ex ante, as well as effects on pharmaceutical markets affiliated to the European ERP system. RESULTS AND CONCLUSION: Pharmaceutical pricing models that fit prices to income and affordability are better in all aspects, as they produce fairer results, while resulting in low external costs for the European ERP network as a whole. Small sets of reference countries are preferred to large baskets, as they produce similar results, while presenting better qualities by increasing the flexibility of the reimbursement system and the transparency of the market. Frontiers Media S.A. 2016-08-31 /pmc/articles/PMC5005395/ /pubmed/27630983 http://dx.doi.org/10.3389/fpubh.2016.00185 Text en Copyright © 2016 Souliotis, Papageorgiou, Politi and Athanasiadis. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Souliotis, Kyriakos Papageorgiou, Manto Politi, Anastasia Athanasiadis, Athanasios Pharmaceutical Pricing Policy in Greece: Toward a Different Path |
title | Pharmaceutical Pricing Policy in Greece: Toward a Different Path |
title_full | Pharmaceutical Pricing Policy in Greece: Toward a Different Path |
title_fullStr | Pharmaceutical Pricing Policy in Greece: Toward a Different Path |
title_full_unstemmed | Pharmaceutical Pricing Policy in Greece: Toward a Different Path |
title_short | Pharmaceutical Pricing Policy in Greece: Toward a Different Path |
title_sort | pharmaceutical pricing policy in greece: toward a different path |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005395/ https://www.ncbi.nlm.nih.gov/pubmed/27630983 http://dx.doi.org/10.3389/fpubh.2016.00185 |
work_keys_str_mv | AT souliotiskyriakos pharmaceuticalpricingpolicyingreecetowardadifferentpath AT papageorgioumanto pharmaceuticalpricingpolicyingreecetowardadifferentpath AT politianastasia pharmaceuticalpricingpolicyingreecetowardadifferentpath AT athanasiadisathanasios pharmaceuticalpricingpolicyingreecetowardadifferentpath |